Sini Li

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity

Lihui Liu, Sini Li, Yan Qu et al. · Cell Reports Medicine · 2023 · 51 citations · Full text

Medicine, Immunology, Oncology +17

ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment

Lihui Liu, Chao Wang, Sini Li et al. · Frontiers in Immunology · 2021 · 46 citations · Full text

Medicine, Cancer Biology, Oncology +17

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Yiting Sun, Jianchun Duan, Wenfeng Fang et al. · BMC Medicine · 2021 · 33 citations · Full text

Medicine, Immunology, Oncology +17

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Peng Ye, Xiaohui Zeng, Liubao Peng et al. · Frontiers in Pharmacology · 2022 · 33 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

Peng Ye, Xiaohui Zeng, Liubao Peng et al. · Advances in Therapy · 2021 · 31 citations

Pharmacy, Oncology, Pharmacotherapy +11